Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.

Auteurs : Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 1582

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.

Auteurs : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 2755-2763

Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.

Auteurs : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Année : 2021
Journal : Mol Cancer Res
Volume : 19
Pages : 1221-1233

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Année : 2021
Journal : BMC Cancer
Volume : 21
Pages : 1292

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Auteurs : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.

Auteurs : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 784947

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.

Auteurs : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S
Année : 2021
Journal : Front Mol Biosci
Volume : 8
Pages : 673042

RTK Inhibitors in Melanoma: From Bench to Bedside.

Auteurs : Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem G
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Sarcoidosis Versus Lymphoma?

Auteurs : Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M, Pepersack T
Année : 2021
Journal : Eur J Case Rep Intern Med
Volume : 8
Pages : 002250

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.

Auteurs : Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 3329-3338

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Année : 2021
Journal : Breast
Volume : 57
Pages : 86-94

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Auteurs : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Année : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Auteurs : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Année : 2021
Journal : Expert Rev Anticancer Ther
Volume : 21
Pages : 81-92

Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.

Auteurs : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart-Gebhart M, Azambuja E
Année : 2021
Journal : J Natl Cancer Inst
Volume : 113
Pages : 462-470

159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)

Auteurs : Eiger D, de Azambuja E, Moreau M, Bondele J, Sotiriou C, Franzoi MA, Brandão M, Rediti M, Wang X, Awada A, Kotecki N
Année : 2020
Journal : Ann Oncol
Volume : 31(2)
Pages : S73-S74

Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review.

Auteurs : Laila B, Vinciane L, Michael V, Patrick F, Awada A, Maria GG, Liberale G
Année : 2020
Journal : Surg Oncol
Volume : 35
Pages : 520-526

Rare Features of Dermatomyositis in a Patient with Ovarian Cancer.

Auteurs : Dal Lago L, Vandergheynst F, Awada A, Pepersack T
Année : 2020
Journal : Eur J Case Rep Intern Med
Volume : 7
Pages : 001946

Oncology care: keep it going, Learn – Improve – Act (white paper BE, IPSEN, ALL-BE-000191- Oct 2020)

Auteurs : Awada A, Ameye F, Bangma CH, Bloemendal H, van Damme J, Gennigens C, de Herder W, Lybaert W, De Meerleer G, Peeters M, Romijn JA, Rottey S, Sedelaar JP, Seront E, Stouthard JM, Suelmann B, Tuytten T, Valk G, De Vries S, Willemse P
Année : 2020
Journal : IPSEN
Volume : -
Pages : -

Clinical management of first-line advanced triple-negative breast cancer patients

Auteurs : Rediti M, Punie K, de Azambuja E, Naert E, Taylor D, Duhoux FP, Denys H, Awada A, Wildiers H, Ignatiadis M
Année : 2020
Journal : Belgian J Medical Oncology
Volume : 14(7)
Pages : 333-338